Evidence map›Paper›PMID 42943229›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Bioequivalence Assessment of Sitagliptin/Metformin Extended-Release Fixed-Dose Combinations in Healthy Mexican Subjects Under Fasting and Fed Conditions.

Omar Emmanuel Hernández Piña, Porfirio de la Cruz Cruz, Erika Gabriela Guido Ávila, Alberto Martínez Muñoz, José Trinidad Pérez Urizar, Abraham Escobedo-Moratilla

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Omar Emmanuel Hernández PiñaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de Mexico C.P. 05348, Mexico.
Porfirio de la Cruz CruzDoctorado Institucional en Ingeniería y Ciencia de Materiales (DICIM), de la Universidad Autónoma de San Luis Potosí (UASLP), Av. Sierra Leona No. 550 Col. Lomas 2da. Sección, San Luis Potosí C.P. 78210, Mexico.
Erika Gabriela Guido ÁvilaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de Mexico C.P. 05348, Mexico.
Alberto Martínez MuñozFS Scientia Pharma S.A. de C.V (Authorized Third Party), Av. Himno Nacional 1330, Jardín, Vista Hermosa, San Luis Potosí C.P. 78270, Mexico.
José Trinidad Pérez UrizarFS Scientia Pharma S.A. de C.V (Authorized Third Party), Av. Himno Nacional 1330, Jardín, Vista Hermosa, San Luis Potosí C.P. 78270, Mexico.ORCID 0000-0003-0642-0033
Abraham Escobedo-MoratillaAsofarma de México S.A. de C.V., Av. Santa Fe 485, Lomas de Santa Fe, Contadero, Cuajimalpa de Morelos, Ciudad de Mexico C.P. 05348, Mexico.ORCID 0000-0003-4676-1625

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bioequivalenceextended-releasefixed-dose combinationfood effectmetforminpharmacokineticssitagliptinType 2 Diabetes

Identifiers

PMID42943229
PMCPMC13708307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.